{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,6]],"date-time":"2026-09-06T10:31:44Z","timestamp":1788690704812,"version":"build-2803163510"},"reference-count":65,"publisher":"Elsevier BV","issue":"7","license":[{"start":{"date-parts":[[2022,7,1]],"date-time":"2022-07-01T00:00:00Z","timestamp":1656633600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,7,1]],"date-time":"2022-07-01T00:00:00Z","timestamp":1656633600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.jp","jada.ada.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["The Journal of the American Dental Association"],"published-print":{"date-parts":[[2022,7]]},"DOI":"10.1016\/j.adaj.2021.12.008","type":"journal-article","created":{"date-parts":[[2022,3,8]],"date-time":"2022-03-08T17:57:44Z","timestamp":1646762264000},"page":"649-658","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":12,"title":["Emerging antiresorptive medications and their potential implications for dental surgeries"],"prefix":"10.1016","volume":"153","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-8399-9988","authenticated-orcid":false,"given":"Anita","family":"Aminoshariae","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7231-7395","authenticated-orcid":false,"given":"Mark","family":"Donaldson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Horan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Scott A.","family":"Mackey","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"James C.","family":"Kulild","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dale","family":"Baur","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"9","key":"10.1016\/j.adaj.2021.12.008_bib1","doi-asserted-by":"crossref","first-page":"1115","DOI":"10.1016\/S0278-2391(03)00720-1","article-title":"Pamidronate (Aredia) and zoledronate (Zometa) induced avascular necrosis of the jaws: a growing epidemic","volume":"61","author":"Marx","year":"2003","journal-title":"J\u00a0Oral Maxillofac Surg"},{"issue":"2","key":"10.1016\/j.adaj.2021.12.008_bib2","first-page":"99","article-title":"Medication-related osteonecrosis of the jaw: a literature review","volume":"61","author":"Kuroshima","year":"2019","journal-title":"J\u00a0Oral Biosci"},{"key":"10.1016\/j.adaj.2021.12.008_bib3","first-page":"CD012432","article-title":"Interventions for managing medication-related osteonecrosis of the jaw","volume":"10","author":"Beth-Tasdogan","year":"2017","journal-title":"Cochrane Database Syst Rev"},{"key":"10.1016\/j.adaj.2021.12.008_bib4","doi-asserted-by":"crossref","first-page":"116168","DOI":"10.1016\/j.bone.2021.116168","article-title":"Biologic and pathologic aspects of osteocytes in the setting of medication-related osteonecrosis of the jaw (MRONJ)","volume":"153","author":"Aguirre","year":"2021","journal-title":"Bone"},{"issue":"10","key":"10.1016\/j.adaj.2021.12.008_bib5","doi-asserted-by":"crossref","first-page":"1938","DOI":"10.1016\/j.joms.2014.04.031","article-title":"American Association of Oral and Maxillofacial Surgeons position paper on medication-related osteonecrosis of the jaw: 2014 update","volume":"72","author":"Ruggiero","year":"2014","journal-title":"J\u00a0Oral Maxillofac Surg"},{"issue":"2","key":"10.1016\/j.adaj.2021.12.008_bib6","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1016\/j.oooo.2018.09.008","article-title":"Medication-related osteonecrosis of the jaw: definition and best practice for prevention, diagnosis, and treatment","volume":"127","author":"Nicolatou-Galitis","year":"2019","journal-title":"Oral Surg Oral Med Oral Pathol Oral Radiol"},{"issue":"2","key":"10.1016\/j.adaj.2021.12.008_bib7","article-title":"Medication-related osteonecrosis of the jaw: a review","volume":"12","author":"AlDhalaan","year":"2020","journal-title":"Cureus"},{"issue":"3","key":"10.1016\/j.adaj.2021.12.008_bib8","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1159\/000201931","article-title":"Combination of bisphosphonates and antiangiogenic factors induces osteonecrosis of the jaw more frequently than bisphosphonates alone","volume":"76","author":"Christodoulou","year":"2009","journal-title":"Oncology"},{"issue":"4","key":"10.1016\/j.adaj.2021.12.008_bib9","first-page":"135","article-title":"Medication-related osteonecrosis of the jaw: risk factors in patients under biphosphonate versus patients under antiresorptive-antiangiogenic drugs","volume":"66","author":"Ghidini","year":"2017","journal-title":"Minerva Stomatol"},{"key":"10.1016\/j.adaj.2021.12.008_bib10","doi-asserted-by":"crossref","first-page":"8376979","DOI":"10.1155\/2016\/8376979","article-title":"Is GERD a factor in osteonecrosis of the jaw? Evidence of pathology linked to G6PD deficiency and sulfomucins","volume":"2016","author":"Seneff","year":"2016","journal-title":"Dis Markers"},{"issue":"1","key":"10.1016\/j.adaj.2021.12.008_bib11","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1002\/jbmr.2405","article-title":"Diagnosis and management of osteonecrosis of the jaw: a systematic review and international consensus","volume":"30","author":"Khan","year":"2015","journal-title":"J\u00a0Bone Miner Res"},{"issue":"1","key":"10.1016\/j.adaj.2021.12.008_bib12","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1186\/s40729-021-00323-0","article-title":"Clinical considerations for medication-related osteonecrosis of the jaw: a comprehensive literature review","volume":"7","author":"Kawahara","year":"2021","journal-title":"Int J Implant Dent"},{"issue":"2 suppl 6","key":"10.1016\/j.adaj.2021.12.008_bib13","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1016\/S0093-7754(01)90259-3","article-title":"Chemical and biological prerequisites for novel bisphosphonate molecules: results of comparative preclinical studies","volume":"28","author":"Green","year":"2001","journal-title":"Semin Oncol"},{"issue":"7","key":"10.1016\/j.adaj.2021.12.008_bib14","doi-asserted-by":"crossref","first-page":"1211","DOI":"10.1016\/j.ejca.2010.02.041","article-title":"Bisphosphonates and RANK ligand inhibitors for the treatment and prevention of metastatic bone disease","volume":"46","author":"Neville-Webbe","year":"2010","journal-title":"Eur J Cancer"},{"issue":"28","key":"10.1016\/j.adaj.2021.12.008_bib16","doi-asserted-by":"crossref","first-page":"4634","DOI":"10.1200\/JCO.2008.16.2768","article-title":"Bisphosphonate-related osteonecrosis of the jaws: a case-control study of risk factors in breast cancer patients","volume":"26","author":"Kyrgidis","year":"2008","journal-title":"J\u00a0Clin Oncol"},{"issue":"2","key":"10.1016\/j.adaj.2021.12.008_bib17","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1016\/j.joms.2009.03.050","article-title":"Prevalence of osteonecrosis of the jaw in patients with oral bisphosphonate exposure","volume":"68","author":"Lo","year":"2010","journal-title":"J\u00a0Oral Maxillofac Surg"},{"issue":"10","key":"10.1016\/j.adaj.2021.12.008_bib18","doi-asserted-by":"crossref","first-page":"1700","DOI":"10.1359\/jbmr.1997.12.10.1700","article-title":"Elimination and biochemical responses to intravenous alendronate in postmenopausal osteoporosis","volume":"12","author":"Khan","year":"1997","journal-title":"J\u00a0Bone Miner Res"},{"issue":"11","key":"10.1016\/j.adaj.2021.12.008_bib20","doi-asserted-by":"crossref","first-page":"1613","DOI":"10.1007\/s00198-008-0604-4","article-title":"Risk of hip fracture after bisphosphonate discontinuation: implications for a drug holiday","volume":"19","author":"Curtis","year":"2008","journal-title":"Osteoporos Int"},{"issue":"24","key":"10.1016\/j.adaj.2021.12.008_bib21","doi-asserted-by":"crossref","first-page":"2927","DOI":"10.1001\/jama.296.24.2927","article-title":"Effects of continuing or stopping alendronate after 5 years of treatment: the Fracture Intervention Trial Long-term Extension (FLEX): a randomized trial","volume":"296","author":"Black","year":"2006","journal-title":"JAMA"},{"issue":"1","key":"10.1016\/j.adaj.2021.12.008_bib22","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1007\/s10549-010-0866-3","article-title":"Bevacizumab and osteonecrosis of the jaw: incidence and association with bisphosphonate therapy in three large prospective trials in advanced breast cancer","volume":"122","author":"Guarneri","year":"2010","journal-title":"Breast Cancer Res Treat"},{"issue":"5","key":"10.1016\/j.adaj.2021.12.008_bib23","doi-asserted-by":"crossref","first-page":"1341","DOI":"10.1093\/annonc\/mdr435","article-title":"Incidence, risk factors, and outcomes of osteonecrosis of the jaw: integrated analysis from three blinded active-controlled phase III trials in cancer patients with bone metastases","volume":"23","author":"Saad","year":"2012","journal-title":"Ann Oncol"},{"issue":"11","key":"10.1016\/j.adaj.2021.12.008_bib25","first-page":"1243","article-title":"Managing the care of patients receiving antiresorptive therapy for prevention and treatment of osteoporosis: executive summary of recommendations from the American Dental Association Council on Scientific Affairs","volume":"142","author":"Hellstein","year":"2011","journal-title":"JADA"},{"issue":"6","key":"10.1016\/j.adaj.2021.12.008_bib26","doi-asserted-by":"crossref","first-page":"e93","DOI":"10.1016\/j.joms.2010.06.197","article-title":"Rubber dam clamp trauma during endodontic treatment: a risk factor of bisphosphonate-related osteonecrosis of the jaw?","volume":"69","author":"Gallego","year":"2011","journal-title":"J\u00a0Oral Maxillofac Surg"},{"issue":"12","key":"10.1016\/j.adaj.2021.12.008_bib27","first-page":"7687","article-title":"Oral health condition in cancer patients under bisphosphonate therapy","volume":"29","author":"Jardim Caldas","year":"2021","journal-title":"Support Care Cancer"},{"issue":"3","key":"10.1016\/j.adaj.2021.12.008_bib28","doi-asserted-by":"crossref","first-page":"190","DOI":"10.1111\/jop.12963","article-title":"Association between periodontitis and medication-related osteonecrosis of the jaw: a systematic review and meta-analysis","volume":"49","author":"Lorenzo-Pouso","year":"2020","journal-title":"J\u00a0Oral Pathol Med"},{"issue":"1","key":"10.1016\/j.adaj.2021.12.008_bib29","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1111\/j.1600-0757.2011.00435.x","article-title":"Osteoporosis and osteopenia: implications for periodontal and implant therapy","volume":"59","author":"Otomo-Corgel","year":"2012","journal-title":"Periodontol. 2000"},{"issue":"7","key":"10.1016\/j.adaj.2021.12.008_bib30","doi-asserted-by":"crossref","first-page":"771","DOI":"10.1016\/j.bjoms.2020.03.022","article-title":"Dental implants as risk factors for patients with medication-related osteonecrosis of the jaws (MRONJ)","volume":"58","author":"Pichardo","year":"2020","journal-title":"Br J Oral Maxillofac Surg"},{"issue":"suppl 18","key":"10.1016\/j.adaj.2021.12.008_bib31","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1111\/clr.13282","article-title":"The effect of antiresorptive drugs on implant therapy: systematic review and meta-analysis","volume":"29","author":"Stavropoulos","year":"2018","journal-title":"Clin Oral Implants Res"},{"issue":"1","key":"10.1016\/j.adaj.2021.12.008_bib32","doi-asserted-by":"crossref","first-page":"17226","DOI":"10.1038\/s41598-021-96480-8","article-title":"Relationship between tooth extraction and development of medication-related osteonecrosis of the jaw in cancer patients","volume":"11","author":"Soutome","year":"2021","journal-title":"Sci Rep"},{"issue":"4","key":"10.1016\/j.adaj.2021.12.008_bib33","doi-asserted-by":"crossref","first-page":"677","DOI":"10.1016\/j.bone.2010.11.020","article-title":"Denosumab and bisphosphonates: different mechanisms of action and effects","volume":"48","author":"Baron","year":"2011","journal-title":"Bone"},{"issue":"8","key":"10.1016\/j.adaj.2021.12.008_bib34","doi-asserted-by":"crossref","first-page":"1221","DOI":"10.1172\/JCI200317215","article-title":"Role of RANK ligand in mediating increased bone resorption in early postmenopausal women","volume":"111","author":"Eghbali-Fatourechi","year":"2003","journal-title":"J\u00a0Clin Invest"},{"issue":"10","key":"10.1016\/j.adaj.2021.12.008_bib35","doi-asserted-by":"crossref","first-page":"1339","DOI":"10.1007\/s00402-019-03167-x","article-title":"Denosumab treatment for giant-cell tumor of bone: a systematic review of the literature","volume":"139","author":"Luengo-Alonso","year":"2019","journal-title":"Arch Orthop Trauma Surg"},{"issue":"16","key":"10.1016\/j.adaj.2021.12.008_bib36","doi-asserted-by":"crossref","first-page":"4415","DOI":"10.1158\/1078-0432.CCR-12-0578","article-title":"Denosumab induces tumor reduction and bone formation in patients with giant-cell tumor of bone","volume":"18","author":"Branstetter","year":"2012","journal-title":"Clin Cancer Res"},{"issue":"9","key":"10.1016\/j.adaj.2021.12.008_bib37","doi-asserted-by":"crossref","first-page":"1493","DOI":"10.1016\/j.jcms.2017.05.028","article-title":"What is the effect of anti-resorptive drugs (ARDs) on the development of medication-related osteonecrosis of the jaw (MRONJ) in osteoporosis patients: a systematic review","volume":"45","author":"Aljohani","year":"2017","journal-title":"J\u00a0Craniomaxillofac Surg"},{"issue":"12","key":"10.1016\/j.adaj.2021.12.008_bib38","doi-asserted-by":"crossref","first-page":"1139","DOI":"10.1111\/ijcp.12022","article-title":"Denosumab: mechanism of action and clinical outcomes","volume":"66","author":"Hanley","year":"2012","journal-title":"Int J Clin Pract"},{"issue":"9","key":"10.1016\/j.adaj.2021.12.008_bib39","doi-asserted-by":"crossref","first-page":"1125","DOI":"10.1200\/JCO.2010.31.3304","article-title":"Randomized, double-blind study of denosumab versus zoledronic acid in the treatment of bone metastases in patients with advanced cancer (excluding breast and prostate cancer) or multiple myeloma","volume":"29","author":"Henry","year":"2011","journal-title":"J\u00a0Clin Oncol"},{"issue":"9","key":"10.1016\/j.adaj.2021.12.008_bib40","doi-asserted-by":"crossref","first-page":"2648","DOI":"10.1158\/1078-0432.CCR-11-2944","article-title":"Denosumab dose selection for patients with bone metastases from solid tumors","volume":"18","author":"Doshi","year":"2012","journal-title":"Clin Cancer Res"},{"issue":"suppl 3","key":"10.1016\/j.adaj.2021.12.008_bib41","doi-asserted-by":"crossref","first-page":"S1","DOI":"10.6004\/jnccn.2013.0215","article-title":"NCCN task force report: bone health in cancer care","volume":"11","author":"Gralow","year":"2013","journal-title":"J\u00a0Natl Compr Cancer Netw"},{"key":"10.1016\/j.adaj.2021.12.008_bib42","first-page":"CD003474","article-title":"Bisphosphonates and other bone agents for breast cancer","volume":"10","author":"O'Carrigan","year":"2017","journal-title":"Cochrane Database Syst Rev"},{"key":"10.1016\/j.adaj.2021.12.008_bib43","unstructured":"Denosumab-Prolia and Xgeva AHM. Active Health Management. Accessed February 7, 2022. https:\/\/www.activehealth.com\/content\/2018\/10\/Denosumab-Prolia-and-Xgeva-AHM-1.pdf"},{"issue":"8","key":"10.1016\/j.adaj.2021.12.008_bib44","first-page":"4763","article-title":"Associated characteristics and treatment outcomes of medication-related osteonecrosis of the jaw in patients receiving denosumab or zoledronic acid for bone metastases","volume":"29","author":"Ikesue","year":"2021","journal-title":"Support Care Cancer"},{"issue":"1","key":"10.1016\/j.adaj.2021.12.008_bib45","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1007\/s11914-019-00502-4","article-title":"Stopping denosumab","volume":"17","author":"Lamy","year":"2019","journal-title":"Curr Osteoporos Rep"},{"key":"10.1016\/j.adaj.2021.12.008_bib46","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1016\/j.bone.2017.08.003","article-title":"Discontinuation of denosumab therapy for osteoporosis: a systematic review and position statement by ECTS","volume":"105","author":"Tsourdi","year":"2017","journal-title":"Bone"},{"issue":"2","key":"10.1016\/j.adaj.2021.12.008_bib47","doi-asserted-by":"crossref","first-page":"190","DOI":"10.1002\/jbmr.3337","article-title":"Vertebral fractures after discontinuation of denosumab: a post hoc analysis of the randomized placebo-controlled FREEDOM trial and its extension","volume":"33","author":"Cummings","year":"2018","journal-title":"J\u00a0Bone Miner Res"},{"issue":"2","key":"10.1016\/j.adaj.2021.12.008_bib48","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1007\/s10006-020-00909-9","article-title":"Apical surgery in cancer patients receiving high-dose antiresorptive medication-a retrospective clinical study with a mean follow-up of 13 months","volume":"25","author":"Werner Moeller Andersen","year":"2021","journal-title":"Oral Maxillofac Surg"},{"issue":"5","key":"10.1016\/j.adaj.2021.12.008_bib49","doi-asserted-by":"crossref","first-page":"570","DOI":"10.1111\/jcpe.12882","article-title":"Denosumab-related osteonecrosis of the jaw following non-surgical periodontal therapy: a case report","volume":"45","author":"Diniz-Freitas","year":"2018","journal-title":"J\u00a0Clin Periodontol"},{"issue":"3","key":"10.1016\/j.adaj.2021.12.008_bib50","doi-asserted-by":"crossref","first-page":"694","DOI":"10.1002\/jbmr.1479","article-title":"Five years of denosumab exposure in women with postmenopausal osteoporosis: results from the first two years of the FREEDOM extension","volume":"27","author":"Papapoulos","year":"2012","journal-title":"J\u00a0Bone Miner Res"},{"issue":"4","key":"10.1016\/j.adaj.2021.12.008_bib51","doi-asserted-by":"crossref","first-page":"516","DOI":"10.1111\/adj.12217","article-title":"Denosumab and osteonecrosis of the jaws: the pharmacology, pathogenesis and a report of two cases","volume":"59","author":"O\u2019Halloran","year":"2014","journal-title":"Aust Dent J"},{"issue":"6","key":"10.1016\/j.adaj.2021.12.008_bib52","doi-asserted-by":"crossref","first-page":"e437","DOI":"10.1016\/j.oooo.2012.01.046","article-title":"Review of current literature and implications of RANKL inhibitors for oral health care providers","volume":"116","author":"Epstein","year":"2013","journal-title":"Oral Surg Oral Med Oral Pathol Oral Radiol"},{"issue":"3","key":"10.1016\/j.adaj.2021.12.008_bib53","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1563\/aaid-joi-D-19-00351","article-title":"Dental implant placement in patients with a history of medications related to osteonecrosis of the jaws: a systematic review","volume":"47","author":"Sher","year":"2021","journal-title":"J\u00a0Oral Implantol"},{"issue":"6","key":"10.1016\/j.adaj.2021.12.008_bib54","doi-asserted-by":"crossref","first-page":"2443","DOI":"10.1210\/jc.2018-01965","article-title":"Invasive oral procedures and events in postmenopausal women with osteoporosis treated with denosumab for up to 10 years","volume":"104","author":"Watts","year":"2019","journal-title":"J\u00a0Clin Endocrinol Metab"},{"issue":"1","key":"10.1016\/j.adaj.2021.12.008_bib55","doi-asserted-by":"crossref","first-page":"e71","DOI":"10.4317\/medoral.23191","article-title":"Review and update on drugs related to the development of osteonecrosis of the jaw","volume":"25","author":"Eguia","year":"2020","journal-title":"Med Oral Patol Oral Cir Bucal"},{"key":"10.1016\/j.adaj.2021.12.008_bib56","doi-asserted-by":"crossref","first-page":"2684924","DOI":"10.1155\/2018\/2684924","article-title":"The dental management of patients at risk of medication-related osteonecrosis of the jaw: new paradigm of primary prevention","volume":"2018","author":"Di Fede","year":"2018","journal-title":"Biomed Res Int"},{"key":"10.1016\/j.adaj.2021.12.008_bib57","doi-asserted-by":"crossref","first-page":"8071579","DOI":"10.1155\/2018\/8071579","article-title":"Osteonecrosis of the jaw associated with antiangiogenics in antiresorptive-na\u00efve patient: a comprehensive review of the literature","volume":"2018","author":"Pimolbutr","year":"2018","journal-title":"Biomed Res Int"},{"issue":"4","key":"10.1016\/j.adaj.2021.12.008_bib59","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1007\/s10456-017-9562-9","article-title":"Tumor angiogenesis and vascular normalization: alternative therapeutic targets","volume":"20","author":"Viallard","year":"2017","journal-title":"Angiogenesis"},{"key":"10.1016\/j.adaj.2021.12.008_bib60","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1016\/j.ctrv.2016.12.002","article-title":"Cardiovascular toxicity of angiogenesis inhibitors in treatment of malignancy: a systematic review and meta-analysis","volume":"53","author":"Abdel-Qadir","year":"2017","journal-title":"Cancer Treat Rev"},{"issue":"2","key":"10.1016\/j.adaj.2021.12.008_bib61","doi-asserted-by":"crossref","first-page":"400","DOI":"10.7150\/thno.16767","article-title":"Limited tumor tissue drug penetration contributes to primary resistance against angiogenesis inhibitors","volume":"7","author":"Torok","year":"2017","journal-title":"Theranostics"},{"key":"10.1016\/j.adaj.2021.12.008_bib62","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1016\/j.ctrv.2018.05.002","article-title":"Assessment of the risk of antiangiogenic agents before and after surgery","volume":"68","author":"Bailey","year":"2018","journal-title":"Cancer Treat Rev"},{"issue":"2","key":"10.1016\/j.adaj.2021.12.008_bib63","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1159\/000513048","article-title":"Brolucizumab: a newly developed anti-VEGF molecule for the treatment of neovascular age-related macular degeneration","volume":"244","author":"Tadayoni","year":"2021","journal-title":"Ophthalmologica"},{"issue":"7","key":"10.1016\/j.adaj.2021.12.008_bib64","doi-asserted-by":"crossref","first-page":"963","DOI":"10.1016\/j.ophtha.2019.12.031","article-title":"Brolucizumab: evolution through preclinical and clinical studies and the implications for the management of neovascular age-related macular degeneration","volume":"127","author":"Nguyen","year":"2020","journal-title":"Ophthalmology"},{"issue":"9","key":"10.1016\/j.adaj.2021.12.008_bib65","doi-asserted-by":"crossref","first-page":"1296","DOI":"10.1016\/j.ophtha.2017.03.057","article-title":"Brolucizumab versus aflibercept in participants with neovascular age-related macular degeneration: a randomized trial","volume":"124","author":"Dugel","year":"2017","journal-title":"Ophthalmology"},{"issue":"12","key":"10.1016\/j.adaj.2021.12.008_bib66","doi-asserted-by":"crossref","first-page":"1589","DOI":"10.1016\/j.ijom.2020.05.017","article-title":"Medication-related osteonecrosis of the jaws associated with intravitreal administration of ranibizumab","volume":"49","author":"Oz","year":"2020","journal-title":"Int J Oral Maxillofac Surg"},{"issue":"3","key":"10.1016\/j.adaj.2021.12.008_bib67","doi-asserted-by":"crossref","DOI":"10.31744\/einstein_journal\/2019RW4628","article-title":"Risk profile for antiangiogenic agent-related osteonecrosis of the jaws","volume":"17","author":"Caminha","year":"2019","journal-title":"Einstein (Sao Paulo)"},{"issue":"3","key":"10.1016\/j.adaj.2021.12.008_bib68","doi-asserted-by":"crossref","first-page":"e326","DOI":"10.4317\/medoral.22858","article-title":"Osteonecrosis of the jaws produced by sunitinib: a systematic review","volume":"24","author":"Vallina","year":"2019","journal-title":"Med Oral Patol Oral Cir Bucal"},{"issue":"1","key":"10.1016\/j.adaj.2021.12.008_bib69","first-page":"375","article-title":"Questionnaire survey of angiogenesis inhibitor-related oral complications based on a nation-wide study in Japan","volume":"16","author":"Yamada","year":"2021","journal-title":"J\u00a0Dent Sci"}],"container-title":["The Journal of the American Dental Association"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S000281772200023X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S000281772200023X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,11]],"date-time":"2025-09-11T04:12:36Z","timestamp":1757563956000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S000281772200023X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,7]]},"references-count":65,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2022,7]]}},"alternative-id":["S000281772200023X"],"URL":"https:\/\/doi.org\/10.1016\/j.adaj.2021.12.008","relation":{},"ISSN":["0002-8177"],"issn-type":[{"value":"0002-8177","type":"print"}],"subject":[],"published":{"date-parts":[[2022,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Emerging antiresorptive medications and their potential implications for dental surgeries","name":"articletitle","label":"Article Title"},{"value":"The Journal of the American Dental Association","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.adaj.2021.12.008","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 American Dental Association. All rights reserved.","name":"copyright","label":"Copyright"}]}}